反向全肩关节置换术是老年肱骨近端骨折最具成本效益的治疗策略:成本-效用分析
本文为加拿大单支付方医疗体系视角的成本-效用分析,比较65岁以上复杂肱骨近端骨折的手术治疗(切开复位内固定、半肩关节置换、反向全肩关节置换)与非手术治疗。结果显示反向全肩关节置换最具成本效益,半肩关节置换次之,切开复位内固定被非手术治疗支配。
要点
- 反向全肩关节置换较非手术治疗的增量成本-效用比为7476加元/质量调整生命年
- 半肩关节置换较非手术治疗的增量成本-效用比为25759加元/质量调整生命年
- 切开复位内固定成本更高且效果更差,被非手术治疗支配
核心结论
- 基于该经济学分析,反向全肩关节置换是65岁以上成人复杂肱骨近端骨折的首选治疗策略,尽管前期成本较高。
- 作者认为现有证据下模型敏感的参数不太可能改变到足以改变模型结果的程度。
- 作者认为临床医生可以自信地推荐反向全肩关节置换用于65岁以上成人肱骨近端骨折,并鼓励倡导该干预为具有成本效益的做法,尤其是在资源管理为核心原则的公共资助医疗体系中。
研究设计与样本
- 成本-效用分析,比较反向全肩关节置换、半肩关节置换、切开复位内固定与65岁以上成人复杂肱骨近端骨折非手术治疗,时限为终生,视角为单支付方医疗体系。
- 术后2年内的短期和中期并发症用决策树建模,长期结局通过马尔可夫模型估计。
- 模型队列为75岁、诊断为粉碎性(三部分或四部分)肱骨近端骨折的患者,其中90%为女性;队列平均年龄和性别构成基于本分析中开展的系统综述。
- 成本为2020年加元,来自区域成本数据库;转移概率和健康效用来自已发表文献。
- 证据等级为Level III,经济学与决策分析。
主要发现
- 成对分析和序贯分析均显示反向全肩关节置换是65岁以上成人复杂肱骨近端骨折最具成本效益的策略。
- 与非手术治疗相比,半肩关节置换和反向全肩关节置换的成对增量成本-效用比分别为25759加元/质量调整生命年和7476加元/质量调整生命年。
- 切开复位内固定被非手术治疗支配,即成本更高且效果更差。
- 序贯分析显示切开复位内固定被半肩关节置换支配,半肩关节置换被反向全肩关节置换扩展支配。
- 在50000加元/质量调整生命年的支付意愿阈值下,反向全肩关节置换成为最具成本效益治疗选项的概率为66%。
关键数值与推荐
- 半肩关节置换较非手术治疗的增量成本-效用比为25759加元/质量调整生命年。
- 反向全肩关节置换较非手术治疗的增量成本-效用比为7476加元/质量调整生命年。
- 在50000加元/质量调整生命年的支付意愿阈值下,反向全肩关节置换最具成本效益的概率为66%。
- 结果对以下参数变化敏感:反向全肩关节置换后翻修反向全肩关节置换的概率、反向全肩关节置换的治疗成本,以及除切开复位内固定外所有治疗选项良好状态相关的健康效用;但基于现有证据这些变化均不被认为具有临床现实性。
临床怎么用
- 作者认为临床医生可以自信地推荐反向全肩关节置换用于65岁以上成人肱骨近端骨折的管理。
- 作者鼓励倡导反向全肩关节置换为具有成本效益的做法,尤其是在资源管理为核心原则的公共资助医疗体系中。
局限性
- 结果对反向全肩关节置换后翻修反向全肩关节置换的概率、反向全肩关节置换的治疗成本以及除切开复位内固定外所有治疗选项良好状态相关的健康效用等参数变化敏感,尽管基于现有证据这些变化均不被认为具有临床现实性。
- 作者指出未来高质量试验应继续使用EuroQOL-5D等经过验证的工具收集临床和生活质量结局,以减少参数不确定性并支持决策者理解相关干预的性价比。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Proximal humerus fractures are the second-most common fragility fracture in older adults. Although reverse total shoulder arthroplasty (RTSA) is a promising treatment strategy for proximal humerus fractures with favorable clinical and quality of life outcomes, it is associated with much higher, and possibly prohibitive, upfront costs relative to nonoperative treatment and other surgical alternatives. QUESTIONS/PURPOSES: (1) What is the cost-effectiveness of open reduction internal fixation (ORIF), hemiarthroplasty, and RTSA compared with the nonoperative treatment of complex proximal humerus fractures in adults older than 65 years from the perspective of a single-payer Canadian healthcare system? (2) Which factors, if any, affect the cost-effectiveness of ORIF, hemiarthroplasty, and RTSA compared with nonoperative treatment of proximal humerus fractures including quality of life outcomes, cost, and complication rates after each treatment? METHODS: This cost-utility analysis compared RTSA, hemiarthroplasty, and ORIF with the nonoperative management of complex proximal humerus fractures in adults older than 65 years over a lifetime time horizon from the perspective of a single-payer healthcare system. Short-term and intermediate-term complications in the 2-year postoperative period were modeled using a decision tree, with long-term outcomes estimated through a Markov model. The model was initiated with a cohort of 75-year-old patients who had a diagnosis of a comminuted (three- or four-part) proximal humerus fractures; 90% of the patients were women. The mean age and gender composition of the model's cohort was based on a systematic review conducted as part of this analysis. Patients were managed nonoperatively or surgically with either ORIF, hemiarthroplasty, or RTSA. The three initial surgical treatment options of ORIF, hemiarthroplasty, and RTSA resulted in uncomplicated healing or the development of a complication that would result in a subsequent surgical intervention. The model reflects the complications that result in repeat surgery and that are assumed to have the greatest impact on clinical outcomes and costs. Transition probabilities and health utilities were derived from published sources, with costs (2020 CAD) sourced from regional costing databases. The primary outcome was the incremental cost-utility ratio, which was calculated using expected quality-adjusted life years (QALYs) gained and costs. Sensitivity analyses were conducted to explore the impact of changing key model parameters. RESULTS: Based on both pairwise and sequential analysis, RTSA was found to be the most cost-effective strategy for managing complex proximal humerus fractures in adults older than 65 years. Compared with nonoperative management, the pairwise incremental cost-utility ratios of hemiarthroplasty and RTSA were CAD 25,759/QALY and CAD 7476/QALY, respectively. ORIF was dominated by nonoperative management, meaning that it was both more costly and less effective. Sequential analysis, wherein interventions are compared from least to most expensive in a pairwise manner, demonstrated ORIF to be dominated by hemiarthroplasty, and hemiarthroplasty to be extendedly dominated by RTSA. Further, at a willingness-to-pay threshold of CAD 50,000/QALY, RTSA had 66% probability of being the most cost-effective treatment option. The results were sensitive to changes in the parameters for the probability of revision RTSA after RTSA, the treatment cost of RTSA, and the health utilities associated with the well state for all treatment options except ORIF, although none of these changes were found to be clinically realistic based on the existing evidence. CONCLUSION: Based on this economic analysis, RTSA is the preferred treatment strategy for complex proximal humerus fractures in adults older than 65 years, despite high upfront costs. Based on the evidence to date, it is unlikely that the parameters this model was sensitive to would change to the degree necessary to alter the model's outcome. A major strength of this model is that it reflects the most recent randomized controlled trials evaluating the management of this condition. Therefore, clinicians should feel confident recommending RTSA for the management of proximal humerus fractures in adults older than 65 years, and they are encouraged to advocate for this intervention as being a cost-effective practice, especially in publicly funded healthcare systems wherein resource stewardship is a core principle. Future high-quality trials should continue to collect both clinical and quality of life outcomes using validated tools such as the EuroQOL-5D to reduce parameter uncertainty and support decision makers in understanding relevant interventions' value for money. LEVEL OF EVIDENCE: Level III, economic and decision analysis.
引用
- Abdel Khalik H, Humphries B, Zoratti M, et al. Reverse Total Shoulder Arthroplasty Is the Most Cost-effective Treatment Strategy for Proximal Humerus Fractures in Older Adults: A Cost-utility Analysis. Clin Orthop Relat Res. 2022. PMID: 35507306. doi:10.1097/CORR.0000000000002219
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。